Polish pharmaceutical group Polpharma has appointed Dr Maurice Chagnaud as its new CEO.
He will join the company next week from Lupin where he was a group president with an inhalation remit for Europe, Russia & CIS.
Prior to that Dr Chagnaud held senior roles at Teva, Mylan and Merck Generics during a career that has so far seen him amass more than 20 years of European pharma management experience.
Polpharma operates across Europe, CIS and Central Asia and has manufacturing subsidiaries in Poland, Russia and Kazakhstan. It’s the largest Polish pharmaceutical group and wants Dr Chagnaud to help it become a regional leader in CEE, CIS and Central Asia.
Jerzy Starak, chairman of Polpharma’s supervisory board, said: “Polpharma’s strategic goal is to become a regional leader and grow outside of our current boundaries. We are impressed by the extensive experience of Mr Chagnaud, gained in international companies such as Merck Generics, Teva and Lupin, where his achievements included building regional strategies and transforming organisations to meet new challenges.
“I am confident that he will manage Polpharma effectively, identify and pursue new opportunities, and motivate our team to deliver outstanding performance to secure the long-term growth of our group.”
As Polpharma CEO Dr Chagnaud will succeed Markus Sieger, who has been delegated by the Supervisory Board to exercise supervision over the company for the last six months, and who will remain a member of the Supervisory Board.